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Abstract 
Monoclonal antibodies targeting immune checkpoints are gaining ground in the treatment of melanoma and 
other cancers, and considerable effort is made to identify biomarkers predicting the efficacy of these 
therapies. Our retrospective study was performed on surgical tissue samples (52 lymph node and 34 
cutaneous/subcutaneous metastases) from 30 patients with metastatic melanoma treated with ipilimumab. 
Using a panel of 11 antibodies against different immune cell types, intratumoral immune cell densities were 
determined and evaluated in relation to response to ipilimumab treatment and disease outcome. For most 
markers studied, median immune cell densities were at least 2 times higher in lymph node metastases 
compared to skin/subcutaneous ones, therefore, the prognostic and predictive associations of immune cell 
infiltration were evaluated separately in the two groups of metastases as well as in all samples as a whole. 
Higher prevalence of several immune cell types was seen in lymph node metastases of the responders 
compared to non-responders, particularly FOXP3+ cells and CD8+ T lymphocytes. In subcutaneous or 
cutaneous metastases, on the other hand, significant difference could be observed only in the case of CD16 
and CD68. Associations of labeled cell densities with survival were also found for most cell types studied in 
nodal metastases, and for CD16+ and CD68+ cells in skin/s.c. metastatic cases. Our results corroborate 
previous findings suggesting an association between an immunologically active tumor microenvironment 
and response to ipilimumab treatment, and propose new potential biomarkers for predicting treatment 
efficacy and disease outcome.  
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Précis 
Immunoprofiling of pretreatment metastatic samples from melanoma patients receiving ipilimumab was 
performed using antibodies against different immune cell types, and revealed potential predictive markers 
for treatment efficacy and disease outcome. 
Abbreviations 
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ADCC  Antibody-dependent cellular cytotoxicity 
AEC  3-amino-9-ethylcarbazole 
CRP  C-reactive protein 
NY-ESO-1 New York esophageal squamous cell carcinoma-1 
VEGF  Vascular endothelial growth factor 
Introduction 
Immunotherapeutic modalities of cancer treatment have been increasingly gaining ground in the past few 
years. Understanding the mechanisms regulating antitumor immune response led to development of a new 
class of immunotherapeutic agents targeting molecular interactions blocking T-cell activation, the so called 
immune checkpoint inhibitors [3]. The first such agent, ipilimumab which blocks CTLA-4 (cytotoxic T 
lymphocyte-associated antigen 4), was added to the therapeutic arsenal of advanced melanoma in 2011 [4, 
5]. It also paved the way for agents targeting other immune regulatory pathways, of which antibodies 
blocking PD-1 or its ligand, PD-L1 represent the most promising treatment modality in a widening spectrum 
of tumor types. In a significant part of responding patients, immune checkpoint agents induce durable 
remission, showing unprecedented clinical efficacy in this patient population with advanced stage cancers. 
Nevertheless, generally only a smaller proportion of patients benefit from immune stimulating antibody 
therapy. In the case of ipilimumab, long-term survival was observed in approximately 20% of patients [6]. 
On the other hand, serious side effects, often immune-related, were reported to occur in a higher percentage 
of patients [7]. In order to improve the benefit/risk ratio of individual patients, it is of primary importance to 
search for biomarkers that could predict the likelihood of therapeutic effect.  
Although no validated predictive biomarkers are available yet for routine clinical use of ipilimumab, several 
candidates have been suggested, mainly concerning peripheral blood immune cells or serum factors. The 
most consistent finding was the observation of association between baseline absolute lymphocyte count, or 
its rise during treatment, and response to therapy or survival [8–11]. In some studies, correlation of high 
absolute eosinophil counts, low neutrophil/lymphocyte ratio or absolute monocyte counts, as well as low 
number or therapy-induced decrease of circulating myeloid-derived suppressor cells, with patient survival or 
response to ipilimumab treatment was described [8, 10–12]. Correlations of baseline number or therapy-
induced change in T cells expressing specific, proliferation- or activation-associated markers (e.g. Ki67, 
ICOS) with outcome have also been observed [8, 10]. Moreover, the presence of antibodies to NY-ESO-1 
(New York esophageal squamous cell carcinoma-1) was found to correlate with clinical benefit of 
ipilimumab treatment, and patients with simultaneous presence of anti-NY-ESO-1 CD8+ (but not CD4+) T-
cell response experienced clinical response and a survival advantage more frequently [13]. Among serum 
factors, high levels of lactate dehydrogenase (LDH), inflammatory markers as C-reactive protein (CRP), or 
vascular endothelial factor (VEGF) were found associated with poor outcome in ipilimumab-treated patients 
[8, 9].  
The role of tumor-infiltrating immune cells in predicting the efficacy of CTLA-4 inhibitors was less 
intensely studied. In melanoma patients, ipilimumab therapy enhanced the expression of many immune-
related genes in metastatic tumor samples, and most genes showing higher pretreatment expression in 
responders were immune-related [14]. In the same trial, clinical activity correlated with baseline staining for 
FOXP3 and indoleamine-2,3-dioxygenase (IDO), as well as with an increase in TIL during treatment, while 
no association was observed for pretreatment TIL or other immune cell subsets [15]. Enhanced tumor 
infiltration by CD4+, CD8+, HLA-DR+/CD45RO+ and FOXP3+ cells was reported in melanoma patients 
receiving tremelimumab, but no correlation with the therapeutic effect was observed [16].  
A novel and intriguing field in the study of predictive biomarkers of immune checkpoint inhibitors is 
analysis of somatic mutations and the resulting neoantigens in tumors [17]. Mutational burden was 
associated with long-term clinical benefit in ipilimumab-treated melanoma patients. Moreover, a neoepitope 
signature was identified that predicted the response to CTLA-4 blockade [18]. 
Most of the candidate biomarkers listed above were investigated only in one or a few studies and none of 
them have been validated and can be used in routine clinical practice. The objective of this study was to 
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explore tumor-infiltrating immune cell types as potential biomarkers predicting response to treatment and 
survival in melanoma patients receiving ipilimumab therapy. 
Materials and methods 
Patients and samples. Archived paraffin blocks of surgical tissue samples were collected from patients with 
metastatic melanoma who received ipilimumab treatment from 2010 to 2014 at four centers in Hungary. In 
the study we included only cases with available tumor samples excised within one year before ipilimumab 
therapy and the study population consisted of 30 patients (1-25 lesions per patient). Eighty-six samples were 
selected for the investigations, 52 lymph node metastases and 34 subcutaneous/cutaneous metastases. The 
primary site was cutaneous in 28 cases and unknown in 2 cases. Most patients (n=18) received ipilimumab 
treatment in the Expanded Access Program and 3 patients after drug commercialization (3 mg/kg four times 
every 3 weeks), while 9 patients participated in the CA-184-169 trial (receiving 3 or 10 mg/kg ipilimumab 
doses). Most patients (n=26) had at least one prior systemic treatment; all of them received chemotherapy, 
while 8 also had radiotherapy, 1 received BRAF inhibitor and 2 patients were treated with 
electrochemotherapy. Twenty-six patients received all 4 doses while the remaining 4 patients received 3 
cycles of ipilimumab treatment (3 because of progression and 1 because of adverse events). Response 
assessment was based on immune-related response criteria (irRC) [19]. For our analysis, patients were 
considered “responders” if the best overall response was complete or partial response, or stable disease 
lasting for at least 6 months. Thirteen of the 30 patients belonged to this group, including 3 patients showing 
complete response lasting more than 24 months (27, 49, 57+ months). Patient and sample characteristics are 
shown in Table 1. 
Immunohistochemical detection of immune cell types. Three-µm sections from formalin-fixed, paraffin-
embedded tumor samples were used in the study. Immunohistochemistry was performed as described earlier 
[20–22], using monoclonal antibodies against CD8, CD20cy, CD45RO, CD68 (Dako, Glostrup, Denmark), 
CD16, CD137 (Santa Cruz Biotechnology, Dallas, TX), CD134 (BD Biosciences Eastern Europe, 
Heidelberg, Germany), FOXP3 (236A/E7; eBioscience, San Diego, CA), NKp46 (R&D Systems, Abingdon, 
UK), CD4 and PD-1 (Cell Marque, Rocklin, CA). For detecting staining we used the SSTM One-Step 
Polymer-HRP IHC Detection System (BioGenex, Fremont, CA), 3-amino-9-ethylcarbazole (AEC; Vector 
Laboratories, Inc., Burlingame, CA) for visualization, and hematoxylin counterstaining. 
Evaluation of the immune reactions. Counting of labeled cells was performed by light microscope 
equipped with an eyepiece graticule, independently by two researchers who were blinded to the clinical 
information, and the mean value of their separate counts was used for the analysis. The number of the 
labeled cells within the metastases was registered in at least 10 (median: 20, range: 10–80) randomly chosen 
fields per section, using the graticule of 10×10 squares designating an area of 0.0625 mm2 at 400× 
magnification. These fields were blindly chosen from different, non-adjacent areas of the metastases, 
omitting necrotic areas; in the case of smaller metastases, the whole tumor area was evaluated. Inter-
observer concordance in density values was excellent (correlation coefficients between 0.6814 and 0.9156 
for the different immune cell markers). For patients with more than one sample available, the mean labeled 
cell densities of all metastases studied were also determined. Cutoff levels were set up for each marker, 
based on the median of the given variable in the whole patient cohort, with minor adjustments for better 
discriminating power in some cases (46, 215, 430, 8, 10, 70, 83, 53, 5, 450, and 450 cells/mm2 for CD4, 
CD8, CD45RO, CD134, CD137, FOXP3, PD-1, CD20, NKp46, CD16 and CD68, respectively) in lymph 
node metastases. In cutaneous/s.c. metastases the cutoff values used were 18, 21, 220, 4, 3, 20, 5, 4, 4, 370, 
and 500 cells/mm2, while in the case of all samples evaluated together, they were 24, 155, 440, 8, 7, 60, 28, 
34, 4, 440, and 400 cells/mm2, in the same order. The proportion of patients with a mean cell density higher 
than the cutoff level was determined. 
Statistical analysis. We used the Mann-Whitney U test for statistical evaluation of differences in cell 
densities between different patient groups, χ2 test for comparing the proportions of samples with high cell 
densities, and the Pearson test for analyzing correlation between the densities of the different cell types. The 
Kaplan-Meier method and Mantel-Cox test were applied for evaluating survival. Univariate and multivariate 
Cox regression analyses were also performed using mean immune cell densities and patients’ age as 
continuous, while patient gender, disease stage, ECOG status, number of organs involved, LDH level and 
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previous treatments (chemo-, radiotherapy) as categorical variables. Differences were considered significant 
in the case of p values ≤0.05. Statistics were calculated using the BMDP Statistical Software Pack. 
Results 
We determined the intratumoral density of immune cells expressing the different markers (CD4, CD8, 
CD45RO, CD20, CD134, CD137, FOXP3, PD-1, NKp46, CD16, CD68) (Fig. 1) in 52 lymph node and 34 
cutaneous or subcutaneous metastases. In lymph node metastases, CD45RO+ T lymphocytes, CD16+ cells 
and CD68+ macrophages were the most numerous, followed by CD8+ T lymphocytes, FOXP3+ cells, CD20+ 
B lymphocytes, CD4+ and PD-1+ cells, while cells expressing the CD134 and CD137 activation markers, as 
well as NKp46+ NK cells were present only in small amounts (Fig. 2). For all cell types except CD68+ 
macrophages and NKp46+ NK cells, density values were significantly lower in subcutaneous/cutaneous 
lesions compared to nodal metastases (Fig. 2). Because of the large difference in immune cell densities 
between the two locations, the prognostic and predictive associations of immune cell infiltration were also 
evaluated separately in the two groups of metastases. 
Intratumoral infiltration of the labeled cells was evaluated in relation to response to ipilimumab treatment 
and disease outcome. Patients were categorized in two groups according to clinical efficacy of ipilimumab, 
showing either complete or partial response, or stable disease for at least 6 months (“responders”) or none of 
the above (“nonresponders”). In lymph node metastases, mean densities of CD4+, CD8+, FOXP3+, CD134+ 
lymphocytes, CD20+ B cells and NKp46+ NK cells were significantly higher in the responder group 
compared to nonresponders (Fig. 3). For each cell type, a cutoff value was introduced based on the median 
of the given variable in the whole patient group (see in Materials and methods), and the proportion of 
patients with a mean intratumoral cell density exceeding this value was calculated and analyzed according to 
the efficacy of ipilimumab treatment. In this comparison, the above mentioned lymphocyte markers as well 
as CD137 also showed higher prevalence in the responders than in nonresponders (Table 2). On the other 
hand, in subcutaneous/cutaneous metastases significant difference between responders and nonresponders 
was found only in the proportion of patients with high mean density of CD68+ macrophages and CD16+ cells 
(Table 2). When all samples were evaluated together, significant association with response to treatment was 
found in the case of NK cell density values (p=0.0182; not shown) and for proportion of patients with high 
density of NK cells as well as that of FOXP3+ cells and CD68+ macrophages (Table 2). 
The densities of most of the studied immune cell types strongly correlated with each other and they 
frequently showed coordinate presence. In lymph node metastases, high expression of at least 7 of the 11 
markers studied was found in 6 of the 7 responders (86%), compared to only 3 of 12 nonresponders (25%) 
(p=0.0106).  
Kaplan-Meier analysis of survival according to the mean immune cell density in lymph node metastases 
revealed that high densities were associated with significantly longer overall survival (OS) in the case of 7 
of the 11 cell types studied (Fig. 4a). The potential prognostic effect of immune cell densities evaluated as 
continuous variables (together with disease stage, patients’ age and gender, ECOG status, number of organs 
involved, LDH level and previous treatments) was also analyzed using Cox’s proportional hazards model. In 
univariate analysis CD4+, CD8+, CD45RO+, FOXP3+ and CD16+ cell densities were found significantly 
associated with overall survival (p=0.0290, p=0.0093, p=0.0180, p=0.0083 and p=0.0047, respectively), 
besides ECOG status (p=0.0009) and LDH (p=0.0227). Multivariate analysis including all immune cell 
density values as well as clinicopathologic parameters identified ECOG status (p=0.001) and FOXP3+ cell 
density (p=0.004) as significant independent predictors of survival. Similar associations were found when all 
samples were evaluated together, either using Kaplan-Meier analysis (not shown) or Cox regression 
demonstrating significantly longer survival in case of high number of cells expressing CD4, CD8, CD45RO, 
FOXP3, CD16, CD68 or CD20 (p=0.0348, p=0.0136, p=0.0113, p=0.0121, p=0.0055, p=0.0168, p=0.0372, 
respectively), as well as in cases with better ECOG status (p=0.0026) and normal LDH level (p=0.0006). In 
multivariate analysis, LDH (p=0.001) and the amount of FOXP3+ cells (p=0.016) proved independent 
predictive factors. In the s.c./cutaneous location, on the other hand, the mean density of CD16+ and CD68+ 
cells showed correlation with OS both in Kaplan-Meier analysis (Fig. 4b) and Cox’s proportional hazards 
model (p=0.0197 and p=0.0175, respectively); in this group only LDH level proved independent predictor of 
survival (p=0.002). Disease stage, patients’ age and gender, the number of organs involved, and previous 
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chemo- or radiotherapy were not found significant parameters in univariate or multivariate analyses in either 
group studied. 
Discussion 
The introduction of ipilimumab, the first representative of the new class of immunotherapy, immune 
checkpoint agents, have revolutionized the treatment of metastatic melanoma, and paved the way for other 
immunomodulatory antibodies as PD-1/PD-L1 inhibitors, expanding the range of targeted tumor types. 
However, even in the case of the most efficient immunotherapeutic modalities, the majority of patients does 
not derive clinical benefit but are still at risk of developing side effects. Furthermore, the therapeutic arsenal 
of several tumor types has recently been widened with the introduction of other, potentially effective 
treatment modalities, e.g. targeted therapies, making it even more important to identify clinically usable 
predictive markers which could help in choosing the optimal treatment strategy for a given patient. 
In our study the density of several immune cell types: CD4+, CD8+ and CD45RO+ T cells, CD20+ B cells, 
lymphocytes expressing the activation markers CD134, CD137 or PD-1, FOXP3+ regulatory T cells, 
NKp46+ NK cells, CD68+ macrophages and cells expressing CD16 (Fcγ receptor III) was determined in 
pretreatment surgical tumor samples of melanoma patients receiving ipilimumab therapy. Density values of 
each cell type were evaluated with regard to response to treatment and the outcome of the disease. 
In this study we restricted sample collection to metastases operated within one year before ipilimumab 
therapy, in an attempt to minimize potential changes in immune microenvironment during time elapsed 
between surgery and ipilimumab treatment. Furthermore, we evaluated surgical samples instead of small 
biopsies, and more than one metastasis per patient when possible, to reduce the confounding effect of 
intrapatient heterogeneity. To our knowledge, our study is the first that attempted to correlate density values 
of a panel of infiltrating immune cell types with response to treatment with ipilimumab in an everyday 
clinical setting, outside of clinical trials. 
We found associations of treatment response and survival with intratumoral density of several infiltrating 
immune cell types. In lymph node metastases, the amount of CD4+, CD8+ T lymphocytes, FOXP3+ 
lymphocytes, cells carrying the CD134 activation marker, as well as CD20+ B cells and NKp46+ NK cells 
was higher in responders; the most pronounced difference could be seen in the case of the FOXP3 marker. 
The densities of CD45RO+, PD-1+, CD16+ and CD68+ cells showed correlation with survival, but not with 
treatment response. Analyzing subcutaneous/cutaneous metastases, on the other hand, resulted in significant 
associations of clinical response and survival with CD16+ and CD68+ cell density values. The amount of 
some of these immune cell types as CD8+ T lymphocytes and CD20+ B cells was also found prognostic in an 
earlier study on melanoma metastases (mostly lymph node and skin or soft tissue), while no association with 
survival was observed in the case of FOXP3+ cells [23].  
Our results demonstrating association of T-cell density with the efficacy of ipilimumab therapy fit well the 
recent hypothesis suggesting different sensitivity of the so called “T-cell-inflamed” and “non-inflamed” 
tumors to the various immunotherapeutic approaches, with higher probability of  T-cell-rich tumors to 
benefit from immunotherapies based on blocking immune suppressive mechanisms [24]. In support of this 
hypothesis, correlations between favorable disease outcome after checkpoint blockade and high expression 
of genes related to immune activity have been found in different tumor types [14, 25, 26]. Moreover, CD8+ 
T-cell density in pretreatment biopsies proved predictive of response of melanoma patients to 
pembrolizumab treatment [27], however, no such associations between the amount of infiltrating T-cell 
subsets and clinical activity were apparent in the case of other anti-PD-1/PD-L1 agents or CTLA-4 blocking 
antibodies [15, 16, 25, 28]. A possible explanation for the lack of predictive power of T-cell density in some 
studies could be that they analyzed together metastases of different locations, from patients with different 
tumor types in some cases. A potentially important finding of our study is that in melanoma patients immune 
cell densities as well as their predictive impact were different for lymph node vs. cutaneous/subcutaneous 
metastases, suggesting that evaluating all metastases without distinction according to their locations may not 
be optimal for revealing all differences between responders and nonresponders.  
According to our results, the factor most strongly predicting treatment response was density of FOXP3+ cells 
infiltrating lymph node metastases. Similarly, strong baseline staining for FOXP3 and IDO was found to 
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correlate with benefit from ipilimumab treatment in another study on melanoma patients [15]. The 
upregulation of immunosuppressive mechanisms in the tumors could also be connected to an active immune 
microenvironment, probably acting as counter-regulatory mechanisms. Indeed, Spranger et al. demonstrated 
correlation of IDO, PD-L1 and FOXP3 expression with each other and with the amount of CD8+ T 
lymphocytes in melanoma metastases, and proved in murine models that the presence of these inhibitory 
mechanisms was driven by infiltrating CD8+ T cells [29]. Our study also showed strong correlation between 
densities of FOXP3+ cells and CD8+ or CD45RO+ lymphocytes (p<0.001). Hypothetically, in T-cell-rich 
tumors simultaneously present suppressive mechanisms may be responsible for inhibiting the antitumor 
effect of T lymphocytes, and therapeutic strategies aiming at blocking these mechanisms, such as immune 
checkpoint inhibitors, could be expected to be beneficial in these cases. 
Recent studies have raised the possibility of ADCC-mediated intratumoral regulatory T cell depletion by Fcγ 
receptor expressing monocytes/macrophages as a mechanism of action of anti-CTLA-4 antibody therapy 
[30–33]. In metastases of melanoma patients receiving ipilimumab therapy the density of CD16+CD68+ cells 
was higher in pretreatment samples of responders compared to nonresponders [33]. Our findings partly 
correspond to these results although significant differences in density of CD16+ and CD68+ cells according 
to clinical response was found only in the case of cutaneous/subcutaneous metastases while correlation with 
survival rather than with clinical response was seen in the case of nodal metastases. Together with the 
association of FOXP3+ cell density with treatment response [the present study and 15], these results may 
support a potential role of regulatory T cell killing by CD16+ effector cells in the effect of ipilimumab. We 
also observed a higher amount of the other potential ADCC effector NK cells in responders, however, the 
density of these cells was very low, which may question their possible biological significance. 
We recognize the inherent limitations of our study caused by its retrospective nature. Moreover, the 
availability of sufficient surgical samples limits the number of patients that could be included in 
immunohistochemistry testing. On the other hand, the strengths of our analysis are that its data derived 
mainly from a ‘real world’ patient cohort and that it evaluated pretreatment immune parameters, enabling 
identification of predictive biomarkers that could help making treatment decisions.  
In conclusion, our data suggest that infiltration by FOXP3+ cells, CD4+, CD8+, CD134+ T lymphocytes, 
CD20+ B cells and NKp46+ NK cells in lymph node metastases, as well as the prevalence of CD16+ cells 
and CD68+ macrophages in cutaneous/subcutaneous ones could be considered as candidate predictive 
markers in melanoma patients receiving ipilimumab therapy. Studies on larger patient cohorts are required 
to prospectively validate these and other parameters of tumor immune contexture as potential biomarkers of 
clinical response to ipilimumab treatment of melanoma patients. Investigation of the predictive value of 
these biomarkers in the case of anti-PD-1 or anti-PD-L1 agents as well as of anti-CTLA-4/anti-PD-1 
combination therapies are also warranted. 
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Table 1. Patient and sample characteristics 
 Responders 
(n=13)a 
Nonresponders 
(n=17)a 
p value 
Age – years, median (range) 67 (51–78) 53 (30–66) 0.0000b 
Gender – n (%)    
   female 5 (38) 8 (47) NSc 
   male  8 (62) 9 (63)  
Disease stage – n (%)   NSc 
   III N3 1 (8) 0 (0)  
   IV M1a 4 (31) 2 (12)  
   IV M1b 3 (23) 5 (29)  
   IV M1c 5 (38) 10 (59)  
Number of organs involved   NSc 
   1-2 8 (62) 14 (82)  
   >2 5 (38) 3 (18)  
ECOG performance status   NSc 
   0 10 (77) 10 (59)  
   1 3 (23) 5 (29)  
   2 0 (0) 2 (12)  
LDH   NSc 
   Normal 10 (77) 8 (47)  
   >ULN 3 (23) 9 (53)  
BRAF V600 mutation   NSc 
   Present 5 (38) 3 (18)  
   Absent 4 (31) 6 (35)  
   Unknown 4 (31) 8 (47)  
Progression-free survival – 
months, median (range) 
9 (6–57) 2 (1–5) 0.0000b 
Overall survival – months, 
median (range) 
30 (10–61) 7 (2–30) 0.0000b 
Samples evaluated, all 34 52 NSc 
   lymph node metastases 20 32  
   cutaneous/sc. metastases 14 20  
aIn the analysis, patients were considered responders if the best overall response was complete or partial 
response, or stable disease lasting for at least 6 months. bMann-Whitney test, cχ2 test 
11 
 
Table 2. Relationship of treatment response with proportion of patients with significant mean density of 
immune cells infiltrating metastasesa  
 Lymph node metastases  
(no. of patients: 19) 
Cutaneous/sc. metastases  
(no. of patients: 19) 
All metastases  
(no. of patients: 30) 
Immune cell 
marker 
Resp. 
n=7 
Nonresp. 
n=12 
p value Resp. 
n=9 
Nonresp. 
n=10 
p value Resp. 
n=13 
Nonresp. 
n=17 
p value 
CD4 6 (86) 4 (33) 0.0274 5 (56) 5 (50) 0.8087 8 (62) 9 (53) 0.6377 
CD8 6 (86) 3 (25) 0.0106 4 (44) 5 (50) 0.8087 8 (62) 5 (29) 0.0785 
CD45RO 6 (86) 6 (50) 0.1195 6 (67) 4 (40) 0.2451 7 (54) 5 (29) 0.1758 
CD20 6 (86) 4 (33) 0.0274 3 (33) 5 (50) 0.4625 6 (46) 4 (24) 0.1927 
CD134 5 (71) 3 (25) 0.0480 5 (56) 4 (40) 0.4977 8 (62) 5 (29) 0.0785 
CD137 5 (71) 2 (17) 0.0170 4 (44) 5 (50) 0.8087 7 (54) 7 (41) 0.4906 
FOXP3 6 (86) 1 (8) 0.0009 5 (56) 5 (50) 0.8087 7 (54) 3 (18) 0.0371 
PD-1 5 (71) 5 (42) 0.2101 3 (33) 6 (60) 0.1775 6 (46) 8 (47) 0.9607 
CD16 5 (71) 6 (50) 0.3615 7 (78) 3 (30) 0.0373 8 (62) 6 (35) 0.1533 
CD68 4 (57) 5 (42) 0.5146 8 (89) 3 (30) 0.0094 11 (85) 8 (47) 0.0344 
NKp46b 6 (86) 4 (33) 0.0274 4 (50) 3 (30) 0.1353 10 (83) 7 (41) 0.0232 
aData are presented as number of patients (%). bOne case with lymph node metastasis could not be 
evaluated. Resp.: responder, Nonresp.: nonresponder 
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Figure 1. Immunohistochemical labeling of CD4+, CD8+, CD45RO+, CD134+, CD137+, FOXP3+, PD-1+, 
CD20+, NKp46+, CD16+, and CD68+ cells in metastatic melanoma samples (AEC, red) 
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Figure 2. Density of immune cell types in pretreatment lymph node (n=52) and subcutaneous/cutaneous 
metastasis samples (n=34) from ipilimumab-treated patients. Boxes show first and third quartiles, horizontal 
lines are the medians and whiskers indicate minimum and maximum values. LN: lymph node; cut/s.c: 
cutaneous/subcutaneous 
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Figure 3. Density of immune cell types in pretreatment lymph node metastasis samples from ipilimumab-
treated patients responding (resp.; n=7) or not responding to treatment (nonresp.; n=12). Circles: mean 
density values of samples from individual patients; horizontal line: median 
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Figure 4. Kaplan-Meier curves of overall survival for melanoma patients subdivided according to mean 
density of immune cells in lymph node (a), or cutaneous/subcutaneous metastases (b) 
